Clinical Study on Intraluminal Injection of FOLactis
This clinical study is a single arm, prospective, single center clinical study on the safety, tolerability, and preliminary efficacy of a novel FOLactis in situ vaccine in the treatment of advanced solid tumors with malignant pleural and peritoneal effusion. The safety, tolerability and preliminary efficacy of intraluminal injection of FOLactis combined with systemic anti-tumor therapy will be evaluated.
Solid Tumor|Immune Response|Pleural Effusion, Malignant|Peritoneal Effusion
OTHER: FOLactis
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, Evaluate the safety and tolerability of intraluminal injection of FOLactis combined with systemic anti-tumor therapy, three years
Objective Response Rate, Observation and evaluation of the preliminary efficacy of FOLactis in patients with advanced solid tumors accompanied by malignant pleural and peritoneal effusion, three years|Progression Free Survival, Changes in the levels of cytokines and lymphocyte subsets in the pleural and peritoneal effusion/peripheral blood of subjects before and after FOLactis treatment;, three years|Overall Survival, 1) The changes in pleural and peritoneal effusion/peripheral blood tumor markers in subjects before and after FOLactis treatment; 2) Changes in tumor microenvironment in the chest and abdominal cavities of subjects before and after FOLactis treatment., three years
This clinical study is a single arm, prospective, single center clinical study on the safety, tolerability, and preliminary efficacy of a novel FOLactis in situ vaccine in the treatment of advanced solid tumors with malignant pleural and peritoneal effusion. The safety, tolerability and preliminary efficacy of intraluminal injection of FOLactis combined with systemic anti-tumor therapy will be evaluated.